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Summary. Platelets can contribute to tumor progression
and metastasis. Cancer patients are at increased risk of
thrombosis, and advanced stages of cancer are associated
with thrombocytosis or increased platelet reactivity. Tyro-
sine kinase inhibitors (TKIs) are widely used as a targeted
strategy for cancer treatment, with the aim of prolonging
progression-free survival of the patients. Because of their
broad kinase target spectrum, most TKIs inevitably have
off-target effects. Platelets rely on tyrosine kinase activity
for their activation. Frequently observed side effects are
lowering of platelet count and inhibition of platelet func-
tions, whether or not accompanied by an increased bleed-
ing risk. In this review, we aim to give insights into: (i) 38
TKIs that are currently used for the treatment of different
types of cancer, either on the market or in clinical trials;
(ii) how distinct TKIs can inhibit activation mechanisms
in platelets; and (iii) the clinical consequences of the anti-
platelet effects of TKI treatment. For several TKIs, the
knowledge on affinity for their targets does not align with
the published effects on platelets and reported bleeding
events. This review should raise awareness of the poten-
tial antiplatelet effects of several TKIs, which will be
enhanced in the presence of antithrombotic drugs.
Keywords: cancer; platelets; signaling; therapy; tyrosine
kinase inhibitor.
Introduction
Human blood platelets are required for hemostasis, and
also contribute to pathological thrombosis [1]. Platelets
normally circulate in the blood at a concentration of 150–
450 9 109 L1, with a lifespan of ⁓ 10 days. Thrombocy-
topenia, defined as a platelet concentration below which
bleeding risks increase, is defined as a count of
< 50 9 109 L1. By implication, only a fraction of the
normally circulating platelets seems to be required for
proper hemostasis, as could be demonstrated in mice [2].
Hence, the majority of circulating platelets are likely to
contribute to other physiological processes, which can
include maintenance of vascular integrity, tissue repair,
immune responses, and infection prevention. The exis-
tence of different populations of platelets, primed by their
environment [3], may even suggest a certain degree of spe-
cialization in these functions. Considering the ‘overload’
of circulating platelets, it is not a surprise that these anu-
cleate cells also contribute to pathological processes,
including cancer.
It is well known that cancer patients are at increased
risk for thrombosis [4], and that advanced stages of can-
cer are associated with increased platelet reactivity [5].
Recent studies have also suggested that the growth factor
composition and even the RNA profile of platelets can
change because of the presence of cancer [6,7]. Also,
malignancy can lead to thrombocytosis (elevated platelet
count), which is regarded as a negative predictor of sur-
vival [8]. The suggested mechanism is enhanced platelet
formation by megakaryocytes, resulting from tumor-
derived interleukin-6 production and high thrombopoietin
production in the liver [9]. This points to a cycle of
tumor-induced platelet formation and activation, followed
by growth factor release and tumor promotion and
metastasis. This reciprocal interaction between platelet
activation and tumor growth has recently been reviewed
by others [10]. The model proposed in 2000 is that tumors
secrete chemokines that recruit blood cells, including pla-
telets, and thus promote the process of angiogenesis, i.e.
the formation of new blood vessels from pre-existing ves-
sels, in order to secure tumor development and metastasis
[11]. Platelets contain numerous proangiogenic (as well as
antiangiogenic) molecules in their a-granules, which are
either synthesized by megakaryocytes in the bone marrow
or are taken up via endocytosis [12].
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In the majority of cancers, oncogene-encoded proteins
or growth factor receptors are amplified or mutated,
which either carry intrinsic tyrosine protein kinase activity
or control both tyrosine and serine/threonine kinases in
the downstream signaling pathways. Accordingly, abnor-
mal protein kinase activity is considered to be a hallmark
of tumor biology [13], resulting in altered cell prolifera-
tion, survival, motility, metabolism, and angiogenesis, as
well as evasion of immune responses [14]. This insight has
prompted the search for tyrosine kinase inhibitors (TKIs)
as targeted therapeutic drugs in oncology.
Protein tyrosine kinases are classified into the receptor-
linked tyrosine kinases, e.g. the vascular endothelial
growth factor (VEGF) and platelet-derived growth factor
(PDGF) receptors, and the cytosolic non-receptor kinases,
such as Src family kinases (SFKs), Syk, and Btk. In
tumors, gain-of-function mutations are often seen in the
genes encoding tyrosine kinases, resulting in constitutively
active proteins. Examples of such aberrant oncoproteins
are BCR–ABL and NPM–ALK. These are encoded by
fusion genes that originate from reciprocal translocation
of genetic material between two chromosomes, resulting
in proteins that are ‘always on’, and leading to uncon-
trolled cell division. In the past 15 years, almost 40 TKIs
have been developed and approved for cancer treatment
(Table 1). In most cases, these are small molecules with
relatively high affinity for the so-called targeted kinases,
but often with similar affinities for other tyrosine kinases.
As many of these tyrosine kinases are also expressed in
non-proliferative cells, including platelets, TKIs can
clearly have relevant off-target effects.
Blood platelets are unable to proliferate or differenti-
ate, but show high tyrosine kinase activities in compar-
ison with other cell types. In platelet activation, tyrosine
phosphorylation is one of the key signal transduction
mechanisms. As described below, non-receptor tyrosine
kinases are activated by the collagen receptor glycopro-
tein (GP) VI, C-type lectin-like receptor 2 (CLEC-2), von
Willebrand factor (VWF) receptor, GPIb–IX–V, and
adhesion-regulating integrins [15,16]. In this review, we
aim to give insights into: (i) the TKIs that are currently
used for the treatment of different types of cancer, either
on the market or in clinical trials; (ii) how distinct TKIs
can inhibit activation mechanisms in platelets; and (iii)
the clinical consequences of the antiplatelet effects of TKI
treatment.
Cancer treatment with TKIs
TKIs are defined as pharmaceutical drugs that inhibit tyr-
osine kinases. The majority of TKIs that are currently in
use are small molecules that can cross the cell membrane.
Their common mode of action is competition with ATP
in the conserved catalytic binding site in the superfamily
of (non)-receptor tyrosine kinases. Because of the compa-
rable structures of the catalytic pockets of tyrosine
kinases, TKIs often target multiple kinases that play roles
in several signaling pathways. At present, ⁓ 40 drugs with
TKI activity have been approved by the USA Food and
Drug Administration, or have entered clinical trials for
anticancer treatment (Table 1).
On the basis of their precise action, TKIs can be classi-
fied into four categories [17]. Type I inhibitors target the
active conformation of the kinase, and compete with the
ATP-binding site (e.g. sunitinib). Type II inhibitors
instead recognize the inactive conformation, and thereby
indirectly compete with ATP by occupying a hydrophobic
pocket near the ATP-binding site. Accordingly, type II
inhibitors are considered to modify the kinase activity in
an allosteric manner (e.g. imatinib and sorafenib).
Type III inhibitors are the so-called allosteric inhibitors.
These bind more distantly from the ATP-binding site,
and inhibit kinase activity via classical allosteric interfer-
ence (e.g. MEK1 inhibitors such as selumetinib). Type IV
inhibitors are also known as covalent inhibitors, forming
an irreversible covalent bond near the active site of the
kinase, usually by reacting with a cysteine. This blocks
the binding of ATP and prevents activation of the kinase
(e.g. ibrutinib and vantedanib).
Although they are directed against specific targets,
almost all TKIs affect multiple kinases. Table 1 provides
an overview of the currently used TKIs that are prescribed
for different types of cancer, together with their target
kinases in tumor cells. The majority of the drugs are tar-
geted at receptor tyrosine kinases for growth factors (epi-
dermal growth factor [EGF], fibroblast growth factor,
PDFG, and VEGF) or for differentiation/proliferation
factors (FLT, FMS, Kit, and Ret). Several of the drugs
also target intracellular tyrosine kinases (ABL, B-Raf, Btk,
Itk, MEK, SFKs, and Syk). Although affinities for individ-
ual kinases will differ, essentially all TKIs have more or
less broader efficacy, which in some cases is intentional.
For instance, both VEGF and PDGF are known to be
important in tumor angiogenesis. Sunitinib, which blocks
signaling via both types of receptor, will thus have a
broader spectrum of action spectrum vatalanib, which tar-
gets only VEGF receptors [18]. In general, the use of TKIs
for the treatment of specific tumors depends on the affinity
for the targeted kinases [19] and the pharmacokinetics at
the indicated dosages and with treatment regimens [20]
(Table 1). As far as is understood, the ultimate specificity
is not strongly correlated with chemical structure or the
subfamily of the targeted kinase [18].
Receptor-linked tyrosine kinases are also abundantly
expressed in non-tumor cells, and treatment with TKIs
will inevitably have off-target effects, thus interfering with
the normal function of non-diseased cells and tissues.
This can explain the side effects of treatment, varying
from general complications such as fatigue, diarrhea, and
nausea, to specific complications such as hand–foot syn-
drome [21]. In spite of drug-to-drug variations, many
TKIs can cause skin toxicity, even in > 50% of patients
© 2018 International Society on Thrombosis and Haemostasis
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[22]. For antiangiogenic TKIs, ‘blood-related’ side effects
have been reported, such as hypertension, myelosuppres-
sion, and bleeding [23]. Incidentally, on-treatment cardio-
vascular events have also been reported, e.g. linked to
affected vascular integrity of the endothelium [24]. TKI
effects on the vessel wall comprise endothelial dysfunction
and increased capillary leakage [25], which may con-
tribute to an increased bleeding tendency. Paradoxically,
drugs affecting the integrity of endothelial cells can shift
the hemostatic balance in favor of thrombosis; this may
explain why treatment with specific TKIs has been associ-
ated with an increase in arterial thromboembolic events
in cancer patients [25,26].
Despite the clinical benefits of the prescribed TKIs,
some of the patients who initially respond to the therapy
experience a relapse, e.g. because of acquired drug resis-
tance of the tumor [14]. In such cases, the treatment
schedule is adjusted or a switch is made to an alternative
TKI as a second-line or third-line treatment (Table 1). In
specific cases, several TKIs can be combined for effective
blockade of one or two signaling pathways [14,21]. Fur-
thermore, chemotherapy or radiation therapy can be com-
plemented with TKI treatment [13].
Protein tyrosine kinases implicated in platelet activation
A global overview of platelet tyrosine kinase signaling
underneath several receptors, as well as the downstream
platelet responses, is given in Table 2.
GPVI signaling Collagen-induced platelet activation is
established via the tyrosine kinase-linked receptor GPVI,
which is a member of the immunoglobulin superfamily.
GPVI is linked to the Fc receptor c chain (FcRc), which
contains two immunoreceptor tyrosine-based activation
motifs (ITAMs) that require phosphorylation to mediate
platelet activation [27]. Ligand binding and dimerization
of the GPVI–FcRc complex leads to activation of the
SFK isoforms Src, Fyn, and Lyn, which, in turn, phos-
phorylate the FcRc ITAM tyrosine residues to recruit
and phosphorylate Syk [1,28]. The tyrosine kinases SFK
and Syk also phosphorylate downstream targets, includ-
ing the transmembrane adapter linker for activated T cells
(LAT) and Src homology 2 domain-containing leukocyte
phosphoprotein (SLP76). The consequence is the forma-
tion of a large signaling complex, including LAT, SLP76,
Btk, isoforms of phosphoinositide 3-kinase (PI3K), and
Tec family kinases [29]. A key downstream event is the
phosphorylation and activation of the second messenger-
generating phospholipase (PLC) c2, resulting in Ca2+
mobilization and protein kinase C activity. Further
responses are integrin activation, thromboxane A2 release,
granule secretion, and phosphatidylserine exposure.
CLEC-2 signaling A similar powerful activation path-
way of platelets is induced via CLEC-2, a C-type lectin
receptor that also acts through tyrosine phosphorylation.
Known ligands of this receptor are podoplanin (ex-
pressed in tumor tissue, among other tissues) and the
snake venom rhodocytin. Signaling occurs through a so-
called hem-ITAM motif [30]. The clustering of CLEC-2
induces events that are more or less similar to those
described for GPVI. Starting with the tyrosine phospho-
rylation of SFK and Syk, a signaling complex including
Tec family tyrosine kinases is formed, resulting in PLCc2
and PI3K activation. The consequences are, again, inte-
grin activation, granule release, and thromboxane A2
production [30].
GPIb–IX–V signaling Interaction of VWF with the
GPIb–IX–V receptor is one of the first steps in platelet
tethering and adhesion under shear flow [1]. This interac-
tion causes only weak signaling, e.g. leading to restructur-
ing of the actin cytoskeleton, with, under certain
conditions, phosphorylation of SFKs (Src, Fyn, and Lyn)
and activation of PI3K isoforms [1]. Integrin aIIbb3 acti-
vation and platelet spreading result from this.
Integrin-dependent signaling Platelet integrins, in partic-
ular aIIbb3, a2b1, and avb3, regulate adhesion, aggrega-
tion, and thrombus formation [28]. Especially regarding
integrin aIIbb3 (ligands: fibrinogen, VWF, and other
matrix proteins) much research has been performed on
the outside-in signaling events triggered by the occupied,
activated conformation. Several tyrosine kinases are
implicated in this signaling pathway, including FAK,
Pyk2, Src, SLP76, and Syk [29,31].
Effects of TKIs on platelet function
Tyrosine kinases are targeted by TKIs as a treatment for
cancer, their most important effect being the prolongation
Table 2 Protein tyrosine kinases implicated in platelet activation
responses: global overview of tyrosine kinases implicated in signaling
via key platelet receptors, as well as downstream platelet responses.
Summarized from [1,16,28,30]
Receptor
Signaling tyrosine kinases
Platelet responseSFK Other
GPVI Src, Fyn, Lyn,
Fgr
Btk, Syk, Tec Ca2+ mobilization,
integrin activation,
degranulation
CLEC-2 Src, Fyn, Lyn Btk, Syk, Tec Ca2+ mobilization,
integrin activation,
degranulation
GPIb–IX–V Src, Fyn, Lyn Btk Integrin activation
Integrin
aIIbb3
Src, Fyn, Lyn FAK, Syk,
SLP76, Pyk2
Spreading,
outside-in signaling,
clot retraction
CLEC-2, C-type lectin-like receptor 2; GP, glycoprotein; SFK, Src
family kinase; SLP76, Src homology 2 domain-containing leukocyte
phosphoprotein.
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of progression-free survival. Given the presence of on-tar-
get or related off-target tyrosine kinases in megakary-
ocytes and platelets, it is to be expected that several TKIs
will interfere with platelet formation and/or platelet acti-
vation processes.
To provide an overview, we evaluated the inhibition
profiles of TKIs (22 in total) against target protein tyro-
sine kinases that are known to be expressed in platelets
[32]. Notably, the majority of these TKIs showed rela-
tively low affinities for kinases with crucial roles in plate-
let activation processes (SFKs, Syk, Btk, MEK, and
Eph), exceptions being bosutinib, dasatinib, fostamatinib,
nintedanib, and sunitinib (Fig. 1). For such an in vitro
affinity-based analysis [18,19,33], it should be realized that
the presence of blood plasma and blood cells can pro-
foundly change the bioavailability of a TKI, apart from
its metabolic and pharmacokinetic profile. Notably,
bleeding symptoms have been reported for 11 of these
TKIs. For individual TKIs, on the basis of their known
targets, we have summarized in Table 3 which of these
targets are expressed in platelets. Furthermore, we made
an inventory of the published effects of these TKIs on
platelet responses.
Ibrutinib is a covalently acting TKI that is targeted at
Btk and Tec, which probably explains the strong effects
observed on platelets [34]. It is frequently used for the treat-
ment of mantle cell lymphoma and chronic lymphocytic
leukemia (CLL). Emerging data suggest that ibrutinib
could also be used to treat solid tumors [35], and it has been
shown to inhibit several other kinases, such as Itk, JAK3,
Hck, Blk, EGF receptor (EGFR), ErbB2, and ErbB4 [36].
Ibrutinib treatment is associated with a risk of bleeding
[34,37,38]. Being the most investigated TKI with regard to
platelets, ibrutinib has been shown to potently inhibit
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collagen-induced responses of platelets from patients
receiving treatment [39–44]. Efficient inhibition by ibrutinib
of the GPVI pathway (in response to collagen or collagen-
related peptide) has been demonstrated to proceed via
reduced PLCc2 phosphorylation [42]. In treated patients,
the suppression of collagen-induced platelet aggregation
has been shown to correlate with the occurrence of bleeding
events [42]. Subsequent studies showed that ibrutinib sup-
pressed multiple (mostly) GPVI-dependent platelet
responses, including adhesion, spreading, calcium fluxes,
secretion, phosphatidylserine exposure, and clot retraction
[40,43]. In addition, evidence was obtained for reduced
aIIbb3-dependent outside-in signaling, linked to thrombus
instability in vitro [40]. Several studies have confirmed that
Btk can act as a central target of ibrutinib in GPVI-stimu-
lated platelets, although downstream tyrosine kinases may
be affected as well [40,42,44]. In vitro, ibrutinib was found
to fully inhibit the tyrosine phosphorylation of Src and
PLCc2 [42]. Other affected events were the phosphoryla-
tion of Fyn, Lyn, Btk, Tec, and Syk [40,44]. Together, these
findings point to potent suppression by ibrutinib of the
GPVI signalosome, with the Tec family kinases as the
major targets.
The second-generation drug acalabrutinib is a more
selective and irreversible Btk inhibitor. In a clinical trial
with patients with relapsed CLL, acalabrutinib showed
promising safety and efficacy profiles, although some
minor bleeds were still reported [45]. A recent study com-
paring treatment with ibrutinib and treatment with acal-
abrutinib indicated that both compounds impaired
platelet aggregation responses after collagen receptor
stimulation [46]. Both drugs inhibited platelet Btk and
Tec at physiological concentrations, whereas only ibruti-
nib inhibited SFK isoforms. This provided an explanation
for why only ibrutinib, and not acalabrutinib, caused dys-
functional thrombus formation [46].
Imatinib, which targets the oncogenic kinase BCR–
ABL, was the first TKI developed for chronic myeloid
leukemia (CML). Imatinib is known to block Kit and
PDGF receptors, as well as Erk and Akt isoforms [47].
This TKI has been reported to cause thrombocytopenia
in 18% of the treated patients, with hemorrhages also
being reported [48]. Despite the high efficacy of imatinib,
15% of patients appear to develop clinical resistance and
relapse after initial response to therapy.
Dasatinib and nilotinib have been developed as second-
generation BCR–ABL inhibitors for the treatment of
CML. Two case reports showed that dasatinib could
induce a bleeding diathesis correlated with platelet dys-
function, which was reversed upon cessation of dasatinib
treatment [49,50]. Studies with blood from patients or
healthy subjects showed impairment of platelet aggrega-
tion by dasatinib given in vivo or in vitro [51,52]. In par-
ticular, platelet aggregation in response to collagen,
arachidonic acid and epinephrine was affected [52], along
with collagen-induced thrombus formation [51,53],
suggesting interference with GPVI signaling and other
pathways. The mechanism of dasatinib-induced inhibition
in platelets was elucidated from changes in the protein
phosphorylation profile after collagen stimulation; dasa-
tinib appeared to interfere with SFK, PLC and PI3K
activities [51]. Thrombocytopenia is a relatively common
side effect of dasatinib treatment [54]. This has been pro-
posed to be attributable to reduced megakaryocytopoiesis,
resulting in lower platelet production [55]. The combined
quantitative (via megakaryocytes) and qualitative (via sig-
naling) platelet dysfunction is most likely the reason for
the relatively high bleeding incidence in dasatinib-treated
patients. Imatinib induces less antiplatelet activity and
causes less bleeding at clinically achievable doses than
dasatinib, probably because it is less inhibitory for SFK
isoforms. On the other hand, nilotinib has been reported
to potentiate thrombus formation and increase the risk of
thrombosis [56].
Ponatinib and bosutinib are third-generation BRC–
ABL inhibitors used for the treatment of CML, and are
applicable when patients develop resistance to imatinib.
The use of ponatinib has been associated with bleeding
diatheses, along with changes in platelet count and func-
tion, which may explain the impaired hemostasis [57,58].
One study described inhibitory effects of ponatinib, ima-
tinib and nilotinib on platelet activation, secretion and
aggregation in response to collagen [57]. In this study,
ponatinib appeared to be the most potent platelet inhibi-
tor. Ponatinib increased PFA-100 closure times, probably
by suppressing ITAM signaling via several tyrosine
kinases, including Src, Lyn, Syk, and Btk [57,58]. In con-
trast, imatinib and nilotinib did not affect platelet granule
secretion, procoagulant activity, or aggregation, and only
moderately reduced the tyrosine phosphorylation of Lyn
and Btk as compared with ponatinib [57]. However,
whole blood thrombus formation was reduced by ima-
tinib and ponatinib to similar extents. For bosutinib
(which also targets Src), bleeding has also been reported
[59], although in patients it did not affect platelet aggre-
gation in response to several agonists [52]. In microfluidic
whole blood testing of platelet thrombus formation, bosu-
tinib was found to be less potent than dasatinib [53].
Overall, it appears that the BCR–ABL inhibitors used for
leukemia treatment have an inhibitory effect on platelet
functions, with the possible exception of nilotinib.
Sunitinib, sorafenib and pazopanib are multitarget
TKIs used for the treatment of renal cell carcinoma, with
the aim of inhibiting tumor angiogenesis via interference
with the receptors for VEGF and PDGF. Such multi-
arget TKIs may potentially also inhibit tyrosine kinases
present in platelets. For sunitinib and sorafenib, a meta-
analysis of 23 trials (> 6500 patients) showed an increased
incidence of bleeding events: 16.7% for all grades of
bleeding, and a 2.4% probability of high-grade bleeding
events [60]. For sunitinib, both quantitative and qualita-
tive effects on platelets have been reported. The
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compound can be taken up by platelets from healthy
donors and renal cell carcinoma patients, and hence
reduce platelet functionality in a way that depends on
protein tyrosine phosphorylation [61]. In patients receiv-
ing treatment, this is accompanied by a decrease in plate-
let count [61,62]. For sorafenib, similarly to other TKIs
used for the treatment of renal cell carcinoma, such as
pazopanib, an increased risk of bleeding has also been
observed [63], but effects on platelet function have not
been investigated.
Afatinib is used for the first-line treatment of, particu-
larly, patients with non-small-cell lung cancers [64]. It acts
as an irreversible inhibitor of EGFR and human epider-
mal growth factor receptor. An increased bleeding risk in
patients receiving afatinib has been linked to impaired
platelet function and apoptosis [65]. In particular, afatinib
impaired GPVI-induced platelet responses, including cal-
cium fluxes, integrin activation, secretion, procoagulant
activity, and platelet aggregation (Table 3). On the other
hand, thrombin-induced platelet responses were less
strongly inhibited. Further investigation showed that the
collagen-induced phosphorylation of Akt was decreased
by afatinib [65].
Cabozantinib, cediranib, dovitinib, lenvatinib, rego-
rafinib and other TKIs cotarget the receptor kinase Kit,
which acts as a receptor for stem cell factor in megakary-
ocytopoiesis, regulating platelet production. The Kit
receptor is known to signal via the SFK, PI3K, Ras–
MEK and JAK–STAT pathways [66]. In an analogous
way, the thrombopoietin receptor Mpl signals via JAK2
and Tyk2 as immediate effector kinases, resulting in the
activation of STAT isoforms [67]. For these signaling
pathways, key tyrosine kinases are also present in plate-
lets and/or megakaryocytes (Tables 2 and 3), which raises
the possibility that Kit-targeted TKIs can modulate plate-
let function as well as platelet count. So far, the signaling
effects of these TKIs on platelets have not been investi-
gated in detail. Cabozantinib treatment has been associ-
ated with a higher bleeding risk [63]. Related drugs are
ruxolitinib, pacritinib, and lesaurtinib, which also target
JAK1/2 and are usually prescribed for myeloproliferative
disorders, such as essential thrombocythemia, which is
characterized by an elevated platelet count (thrombocyto-
sis). The latter compounds appear to lower (normalize)
the concentration of circulating platelets [68], most likely
via inhibition of the thrombopoietin pathway in
megakaryocytes. However, the effects on platelet function
are still unclear. It is known that thrombopoietin potenti-
ates agonist-induced platelet activation via JAK2 and
Tyk2 signaling [69]. This indicates that this pathway is
not strong enough to induce platelet activation on its
own. Inhibition of JAK2 in platelets has been reported to
only attenuate collagen-induced responses [70].
For multiple prescribed TKIs with a broad target
range, bleeding symptoms have not been reported
(Table 1). Examples of these are fostamatinib, dovitinib,
and vantedanib, which, on the basis of their affinity pro-
files, should affect SFK and/or MEK isoforms in platelets
(Fig. 1). In these cases, additional research is needed to
verify the effects on platelet count and activation, and to
determine whether there is a bleeding risk. Summarizing
the current knowledge of TKI effects on platelet activa-
tion responses, it appears that the majority of multitarget
TKIs suppress, in particular, GPVI-induced signaling
pathways, but that they can also target kinase events
downstream of other platelet receptors. As the inhibition
of GPVI alone has been shown to prevent occlusive
thrombus formation without causing bleeding [71], it is
most likely that the targeting of pathways downstream of
additional receptors is responsible for an increased bleed-
ing risk with these compounds.
Clinical implications of platelet inhibition with TKIs
Platelets are known to interact with cancer cells in the
blood. Tumors exposed to the bloodstream can activate
platelets, and platelets can stimulate tumor angiogenesis,
growth, and metastasis. The question has been raised
of whether and how interfering in the platelet–cancer
loop via antiplatelet treatment may also influence can-
cer progression. Several studies have reported that
aspirin and P2Y12 receptor inhibitors suppress tumor
angiogenesis in vitro [72] and tumor growth in vivo [73].
A low daily aspirin intake has been associated with a
reduced risk for the development of cancer, as well as
the prevention of metastases [74]. The mechanism is not
completely resolved, but it has been shown that inhibi-
tion of platelets by aspirin decreased their ability to
stimulate cancer cell proliferation through modulation
of the Myc oncoprotein [75]. For other antiplatelet
drugs, clinical evidence of a beneficial effect on cancer
is still lacking.
Of growing interest is the recent finding that platelets
are capable of sequestering bioactive compounds from the
plasma, including growth factors [12,76,77] and RNA spe-
cies [7]. In addition, platelets accumulate the anticancer
drugs bevacizumab [78] and sunitinib (in granules) [61].
Other TKIs can also be taken up by platelets, which usu-
ally is a requirement for interaction with the intracellular
kinases. Whether these TKIs can also be secondarily
released by platelets and, perhaps, then contribute to
tumor inhibition is matter of speculation. Another consid-
eration is that uptake of TKIs by platelets (e.g. in
patients with thrombocytosis) can reduce the availability
of the compounds for tumor inhibition. On the other
hand, it is likely that a decreased aggregation tendency of
platelets (as induced by TKIs) also lowers tumor-induced
platelet activation, and thereby reduces metastasis of
tumor cells. However, the evidence for such a mechanism
is, at best indirect, and further investigation is required.
Taken these findings together, it appears that platelets
can interfere with drug effects in different ways and by
© 2018 International Society on Thrombosis and Haemostasis
1694 B. M. E. Tullemans et al
different mechanisms, which should be taken into account
in therapeutic drug monitoring.
Application of the TKIs axitinib, dasatinib, pazopanib,
sorafenib and sunitinib – all of which may cause bleeding –
can lead to a reduction in the platelet concentration in
blood (Table 3). In cancer patients, thrombocytosis has
been associated with a worse overall prognosis than that
in patients with a normal platelet count [8,9]. In addition,
in glioblastoma patients who underwent concomitant
radiotherapy and chemotherapy, a decrease in platelet
count correlated with longer overall survival [79]. In renal
cell carcinoma patients with metastasis, a reduction in
platelet count after the start of sunitinib treatment was
associated with a better treatment outcome [62]. Although
more research is needed, these studies suggest that platelet
count can be used as one of the parameters to monitor
anticancer treatment efficacy.
Besides platelet count, platelet function can also be
affected by many TKIs, as indicated in Table 3. This sug-
gests that combined platelet count and function tests
could be used in clinical practice to assess the risk of
bleeding upon TKI treatment. For the availability of such
(point-of-care) tests, we refer to the literature [80]. In the
future, it may be possible to use flow-based assays for this
purpose. Our laboratory recently found that this method
detects additive effects of low platelet count and impaired
platelet functionality in patients with a bleeding pheno-
type [81].
It is known that cancer patients are at increased risk for
thrombosis, also referred to as Trousseau’s syndrome [82].
As a consequence, many cancer patients have a history of
cardiovascular disease and are treated with antiplatelet or
anticoagulant drugs. When additional treatment with a
TKI is started, the clinical problem of an enhanced bleed-
ing risk may arise. Another treatment issue is that some
oral anticoagulants and TKIs (e.g. ibrutinib) have a com-
mon metabolic pathway (cytochrome P450 3A4), which
can affect the pharmacokinetics of either drug. These inter-
actions between TKIs and antithrombotic treatments need
to be further investigated.
Conclusions
Several of the TKIs used for the treatment of cancer can
increase the risk of bleeding. For some, but not all, of
these, the bleeding tendency is linked to a lowering of pla-
telet count and/or an impairment of platelet function. On
the basis of their binding profiles, some other TKIs are
predicted to have an antiplatelet effect, although no
bleeding side effects have been reported so far. For a
third group of TKIs, no published data on platelets are
available. Given the suspected role of platelets in tumor
progression, platelet inhibition may be a clinically rele-
vant side effect of several TKIs. Together, the available
knowledge shows that there must be awareness of the
potential antiplatelet effects of TKIs, which are likely to
be further enhanced in combination with antithrombotic
drugs.
Addendum
B. M. E. Tullemans reviewed the literature, compiled
tables and Fig. 1, and wrote the manuscript. J. W. M.
Heemskerk was responsible for the outline, and wrote
and revised the manuscript. M. J. E. Kuijpers was respon-
sible for the outline, reviewed the literature, and wrote
and revised the manuscript.
Acknowledgements
This study was supported by the Maastricht Thrombosis
Expertise Center as part of the Heart and Vascular Cen-
ter (HVC) of the MUMC+.
Disclosure of Conflict of Interests
M. Kuijpers and J. W. M. Heemskerk report receiving
grants from Pfizer during the conduct of the study. B. M.
E. Tullemans states that she has no conflict of interest.
References
1 Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fun-
damentals in hemostasis. Physiol Rev 2013; 93: 327–58.
2 Morowski M, Vogtle T, Kraft P, Kleinschnitz C, Stoll G, Nies-
wandt B. Only severe thrombocytopenia results in bleeding and
defective thrombus formation in mice. Blood 2013; 121: 4938–47.
3 Baaten CCFMJ, Ten Cate H, van der Meijden PEJ, Heemskerk
JWM. Platelet populations and priming in hematological dis-
eases. Blood Rev 2017; 31: 389–99.
4 Franco AT, Corken A, Ware J. Platelets at the interface of
thrombosis, inflammation, and cancer. Blood 2015; 126: 582–8.
5 Cooke NM, Egan K, McFadden S, Grogan L, Breathnach OS,
O’Leary J, Hennessy BT, Kenny D. Increased platelet reactivity
in patients with late-stage metastatic cancer. Cancer Med 2013;
2: 564–70.
6 Sabrkhany S, Kuijpers MJE, van Kuijk SMJ, Sanders L, Pineda
S, Olde Damink SWM, Dingemans AC, Griffioen AW, Oude
Egbrink MGA. A combination of platelet features allows detec-
tion of early-stage cancer. Eur J Cancer 2017; 80: 5–13.
7 Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rusten-
burg F, Schellen P, Verschueren H, Post E, Koster J, Ylstra B,
Ameziane N, Dorsman J, Smit EF, Verheul HM, Noske DP,
Reijneveld JC, Nilsson RJA, Tannous BA, Wesseling P, et al.
RNA-seq of tumor-educated platelets enables blood-based pan-
cancer, multiclass, and molecular pathway cancer diagnostics.
Cancer Cell 2015; 28: 666–76.
8 Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD,
Honn KV. Platelets and cancer: a casual or causal relationship:
revisited. Cancer Metastasis Rev 2014; 33: 231–69.
9 Lin RJ, Afshar-Kharghan V, Schafer AI. Paraneoplastic throm-
bocytosis: the secrets of tumor self-promotion. Blood 2014; 124:
184–7.
10 Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The
platelet–cancer loop. Eur J Intern Med 2013; 24: 393–400.
11 Carmeliet P. Mechanisms of angiogenesis and arteriogenesis.
Nat Med 2000; 6: 389–95.
© 2018 International Society on Thrombosis and Haemostasis
Antiplatelet effects of tyrosine kinase inhibitors 1695
12 Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust
V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, Almog
N, Kieran MW, Folkman J. Platelets actively sequester angio-
genesis regulators. Blood 2009; 113: 2835–42.
13 Hanahan D, Weinberg RA. Hallmarks of cancer: the next gen-
eration. Cell 2011; 144: 646–74.
14 Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Target-
ing cancer with kinase inhibitors. J Clin Invest 2015; 125: 1780–9.
15 Swieringa F, Kuijpers MJ, Heemskerk JW, van der Meijden
PE. Targeting platelet receptor function in thrombus formation:
the risk of bleeding. Blood Rev 2014; 28: 9–21.
16 Levade M, Severin S, Gratacap MP, Ysebaert L, Payrastre B.
Targeting kinases in cancer therapies: adverse effects on blood
platelets. Curr Pharm Des 2016; 22: 2315–22.
17 Wu P, Nielsen TE, Clausen MH. FDA-approved small-mole-
cule kinase inhibitors. Trends Pharmacol Sci 2015; 36: 422–39.
18 Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azi-
mioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT,
Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM,
Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta
SA, et al. A small molecule-kinase interaction map for clinical
kinase inhibitors. Nat Biotechnol 2005; 23: 329–36.
19 Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge
CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT,
Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV,
Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM,
et al. A quantitative analysis of kinase inhibitor selectivity. Nat
Biotechnol 2008; 26: 127–32.
20 Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH,
Huitema AD. Practical guidelines for therapeutic drug monitor-
ing of anticancer tyrosine kinase inhibitors: focus on the phar-
macokinetic targets. Clin Pharmacokinet 2014; 53: 305–25.
21 Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhi-
bitors: what is their mechanism of action? Angiogenesis 2010;
13: 1–14.
22 Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase
inhibitors – a review on pharmacology, metabolism and side
effects. Curr Drug Metab 2009; 10: 470–81.
23 Eskens FA, Verweij J. The clinical toxicity profile of vascular
endothelial growth factor (VEGF) and vascular endothelial
growth factor receptor (VEGFR) targeting angiogenesis inhibi-
tors; a review. Eur J Cancer 2006; 42: 3127–39.
24 Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated
cardiovascular toxicity in chronic myeloid leukemia. J Clin
Oncol 2015; 33: 4210–18.
25 Bair SM, Choueiri TK, Moslehi J. Cardiovascular complica-
tions associated with novel angiogenesis inhibitors: emerging
evidence and evolving perspectives. Trends Cardiovasc Med
2013; 23: 104–13.
26 Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk
of arterial thromboembolic events with sunitinib and sorafenib:
a systematic review and meta-analysis of clinical trials. J Clin
Oncol 2010; 28: 2280–5.
27 Nieswandt B, Watson SP. Platelet–collagen interaction: is GPVI
the central receptor? Blood 2003; 102: 449–61.
28 Senis YA, Mazharian A, Mori J. Src family kinases: at the fore-
front of platelet activation. Blood 2014; 124: 2013–24.
29 Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and
integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost
2005; 3: 1752–62.
30 Navarro-Nunez L, Langan SA, Nash GB, Watson SP. The
physiological and pathophysiological roles of platelet CLEC-2.
Thromb Haemost 2013; 109: 991–8.
31 Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhe-
sion and signaling in platelets. Blood 2004; 104: 1606–15.
32 Burkhart JM, Vaudel M, Gambaryan S, Radau S, Walter U,
Martens L, Geiger J, Sickmann A, Zahedi RP. The first
comprehensive and quantitative analysis of human platelet pro-
tein composition allows the comparative analysis of structural
and functional pathways. Blood 2012; 120: e73–82.
33 Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pal-
lares G, Hocker M, Treiber DK, Zarrinkar PP. Comprehensive
analysis of kinase inhibitor selectivity. Nat Biotechnol 2011; 29:
1046–51.
34 Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV,
DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis,
management and risk reduction strategies. J Thromb Haemost
2017; 15: 835–47.
35 Molina-Cerrillo J, Alonso-Gordoa T, Gajate P, Grande E. Bru-
ton’s tyrosine kinase (BTK) as a promising target in solid
tumors. Cancer Treat Rev 2017; 58: 41–50.
36 Rauf F, Festa F, Park JG, Magee M, Eaton S, Rinaldi C,
Betanzos CM, Gonzalez-Malerva L, LaBaer J. Ibrutinib inhibi-
tion of ERBB4 reduces cell growth in a WNT5A-dependent
manner. Oncogene 2018; 37: 2237–50.
37 Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum
KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones
JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J,
Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, et al.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic
leukemia. N Engl J Med 2013; 369: 32–42.
38 Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current
understanding of bleeding with ibrutinib use: a systematic
review and meta-analysis. Blood Adv 2017; 1: 772–8.
39 Alberelli MA, Innocenti I, Sica S, Laurenti L, De Candia E.
PO-54 – clinical and laboratory characterization of platelet
dysfunction caused by ibrutinib treatment in patients with
chronic lymphocytic leukemia. Thromb Res 2016; 140(Suppl.
1): S196.
40 Bye AP, Unsworth AJ, Vaiyapuri S, Stainer AR, Fry MJ, Gib-
bins JM. Ibrutinib inhibits platelet integrin alphaIIbbeta3 out-
side-in signaling and thrombus stability but not adhesion to
collagen. Arterioscler Thromb Vasc Biol 2015; 35: 2326–35.
41 Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S,
Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, Khot A,
Sandhu S, Keating MJ, Nandurkar H, Tam CS. Ibrutinib inhi-
bits collagen-mediated but not ADP-mediated platelet aggrega-
tion. Leukemia 2015; 29: 783–7.
42 Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet
AS, Bordet JC, Tam C, Sie P, Ysebaert L, Payrastre B. Ibruti-
nib treatment affects collagen and von Willebrand factor-depen-
dent platelet functions. Blood 2014; 124: 3991–5.
43 Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM,
Nghiem K, Sun C, Valdez J, Niemann CU, Herman SE, Saba
N, Soto S, Marti G, Uzel G, Holland SM, Lozier JN, Wiestner
A. Incidence and risk factors of bleeding-related adverse events
in patients with chronic lymphocytic leukemia treated with ibru-
tinib. Haematologica 2015; 100: 1571–8.
44 Rigg RA, Aslan JE, Healy LD, Wallisch M, Thierheimer ML,
Loren CP, Pang J, Hinds MT, Gruber A, McCarty OJ. Oral
administration of Bruton’s tyrosine kinase inhibitors impairs
GPVI-mediated platelet function. Am J Physiol Cell Physiol
2016; 310: C373–80.
45 Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Dev-
ereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen
P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J,
Johnson D, Huang J, Wang X, Kaptein A, et al. Acalabrutinib
(ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J
Med 2016; 374: 323–32.
46 Bye AP, Unsworth AJ, Desborough MJ, Hildyard CAT,
Appleby N, Bruce D, Kriek N, Nock SH, Sage T, Hughes CE,
Gibbins JM. Severe platelet dysfunction in NHL patients receiv-
ing ibrutinib is absent in patients receiving acalabrutinib. Blood
Adv 2017; 1: 2610–23.
© 2018 International Society on Thrombosis and Haemostasis
1696 B. M. E. Tullemans et al
47 Yang K, Fu LW. Mechanisms of resistance to BCR-ABL TKIs
and the therapeutic strategies: a review. Crit Rev Oncol Hematol
2015; 93: 277–92.
48 Breccia M, Stefanizzi C, Cannella L, Latagliata R, Frustaci
AM, Carmosino I, Santopietro M, Alimena G. Differences in
hematological and non-hematological toxicity during treatment
with imatinib in patients with early and late chronic phase
chronic myeloid leukemia. Leuk Lymphoma 2008; 49: 2328–32.
49 Kostos L, Burbury K, Srivastava G, Prince HM. Gastrointesti-
nal bleeding in a chronic myeloid leukaemia patient precipitated
by dasatinib-induced platelet dysfunction: case report. Platelets
2015; 26: 809–11.
50 Mustafa Ali MK, Sabha MM, Al-Rabi KH. Spontaneous
subdural hematoma in a patient with Philadelphia chromo-
some-positive acute lymphoblastic leukemia with normal pla-
telet count after dasatinib treatment. Platelets 2015; 26: 491–
4.
51 Gratacap MP, Martin V, Valera MC, Allart S, Garcia C, Sie P,
Recher C, Payrastre B. The new tyrosine-kinase inhibitor and
anticancer drug dasatinib reversibly affects platelet activation
in vitro and in vivo. Blood 2009; 114: 1884–92.
52 Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine
kinase inhibitor-induced platelet dysfunction in patients with
chronic myeloid leukemia. Blood 2009; 114: 261–3.
53 Li R, Grosser T, Diamond SL. Microfluidic whole blood testing
of platelet response to pharmacological agents. Platelets 2017;
28: 457–62.
54 Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer
PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbon-
nier A, Khoroshko N, Paquette RL, Deininger M, Collins RH,
Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hoch-
haus A. Intermittent target inhibition with dasatinib 100 mg
once daily preserves efficacy and improves tolerability in ima-
tinib-resistant and -intolerant chronic-phase chronic myeloid
leukemia. J Clin Oncol 2008; 26: 3204–12.
55 Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP.
Dasatinib enhances megakaryocyte differentiation but inhibits
platelet formation. Blood 2011; 117: 5198–206.
56 Alhawiti N, Burbury KL, Kwa FA, O’Malley CJ, Shuttleworth
P, Alzard M, Hamadi A, Grigg AP, Jackson DE. The tyrosine
kinase inhibitor, nilotinib potentiates a prothrombotic state.
Thromb Res 2016; 145: 54–64.
57 Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber
A, Druker BJ, McCarty OJ. The BCR-ABL inhibitor ponatinib
inhibits platelet immunoreceptor tyrosine-based activation motif
(ITAM) signaling, platelet activation and aggregate formation
under shear. Thromb Res 2015; 135: 155–60.
58 Neelakantan P, Marin D, Laffan M, Goldman J, Apperley J,
Milojkovic D. Platelet dysfunction associated with ponatinib, a
new pan BCR-ABL inhibitor with efficacy for chronic myeloid
leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Haematologica 2012; 97: 1444.
59 Pasvolsky O, Leader A, Iakobishvili Z, Wasserstrum Y, Kor-
nowski R, Raanani P. Tyrosine kinase inhibitor associated vas-
cular toxicity in chronic myeloid leukemia. Cardiooncology
2015; 1: 5–14.
60 Je Y, Schutz FAB, Choueiri TK. Risk of bleeding with vascular
endothelial growth factor receptor tyrosine-kinase inhibitors
sunitinib and sorafenib: a systematic review and meta-analysis
of clinical trials. Lancet Oncol 2009; 10: 967–74.
61 Sabrkhany S, Griffioen AW, Pineda S, Sanders L, Mattheij N,
van Geffen JP, Aarts MJ, Heemskerk JW, Oude Egbrink MG,
Kuijpers MJ. Sunitinib uptake inhibits platelet function in can-
cer patients. Eur J Cancer 2016; 66: 47–54.
62 Hamilton Z, Lee HJ, Jimenez J, Lane BR, Wang S, Beksac AT,
Gillis K, Alagh A, Tobert C, Randall JM, Kane CJ, Millard F,
Campbell SC, Derweesh IH. Change in platelet count as a
prognostic indicator for response to primary tyrosine kinase
inhibitor therapy in metastatic renal cell carcinoma. BJU Int
2016; 118: 927–34.
63 Crist M, Hansen E, Chablani L, Guancial E. Examining the
bleeding incidences associated with targeted therapies used in
metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2017;
120: 151–62.
64 Keating GM. Afatinib: a review of its use in the treatment of
advanced non-small cell lung cancer. Drugs 2014; 74: 207–21.
65 Cao H, Bhuyan AAM, Umbach AT, Bissinger R, Gawaz M,
Lang F. Inhibitory effect of afatinib on platelet activation and
apoptosis. Cell Physiol Biochem 2017; 43: 2264–76.
66 Cardoso HJ, Figueira MI, Socorro S. The stem cell factor
(SCF)/c-KIT signalling in testis and prostate cancer. J Cell
Commun Signal 2017; 11: 297–307.
67 Hitchcock IS, Kaushansky K. Thrombopoietin from beginning
to end. Br J Haematol 2014; 165: 259–68.
68 Quintas-Cardama A, Verstovsek S. Spleen deflation and
beyond: the pros and cons of Janus kinase 2 inhibitor therapy
for patients with myeloproliferative neoplasms. Cancer 2012;
118: 870–7.
69 Moore SF, Hunter RW, Harper MT, Savage JS, Siddiq S,
Westbury SK, Poole AW, Mumford AD, Hers I. Dysfunction
of the PI3 kinase/Rap1/integrin alpha(IIb)beta(3) pathway
underlies ex vivo platelet hypoactivity in essential thrombo-
cythemia. Blood 2013; 121: 1209–19.
70 Lu WJ, Lin KC, Huang SY, Thomas PA, Wu YH, Wu HC,
Lin KH, Sheu JR. Role of a Janus kinase 2-dependent signaling
pathway in platelet activation. Thromb Res 2014; 133: 1088–96.
71 Andrews RK, Arthur JF, Gardiner EE. Targeting GPVI as a
novel antithrombotic strategy. J Blood Med 2014; 5: 59–68.
72 Etulain J, Fondevila C, Negrotto S, Schattner M. Platelet-
mediated angiogenesis is independent of VEGF and fully inhib-
ited by aspirin. Br J Pharmacol 2013; 170: 255–65.
73 Mezouar S, Darbousset R, Dignat-George F, Panicot-Dubois
L, Dubois C. Inhibition of platelet activation prevents the P-
selectin and integrin-dependent accumulation of cancer cell
microparticles and reduces tumor growth and metastasis
in vivo. Int J Cancer 2015; 136: 462–75.
74 Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW,
Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a
study of incident cancers during randomised controlled trials.
Lancet 2012; 379: 1591–601.
75 Mitrugno A, Sylman JL, Ngo AT, Pang J, Sears RC, Williams
CD, McCarty OJ. Aspirin therapy reduces the ability of plate-
lets to promote colon and pancreatic cancer cell proliferation:
implications for the oncoprotein c-MYC. Am J Physiol Cell
Physiol 2017; 312: C176–89.
76 Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA,
Folman CC, Broxterman HJ, Pinedo HM. Platelet: transporter
of vascular endothelial growth factor. Clin Cancer Res 1997; 3:
2187–90.
77 Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Con-
nors S, Oenick M, D’Amato RJ, Klement GL, Folkman J.
VEGF, PF4 and PDGF are elevated in platelets of colorectal
cancer patients. Angiogenesis 2012; 15: 265–73.
78 Verheul HM, Lolkema MP, Qian DZ, Hilkes YH, Liapi E,
Akkerman JW, Pili R, Voest EE. Platelets take up the mono-
clonal antibody bevacizumab. Clin Cancer Res 2007; 13: 5341–
7.
79 Williams M, Liu ZW, Woolf D, Hargreaves S, Michalarea V,
Menashy R, Kooner I, Wilson E. Change in platelet levels dur-
ing radiotherapy with concurrent and adjuvant temozolomide
for the treatment of glioblastoma: a novel prognostic factor for
survival. J Cancer Res Clin Oncol 2012; 138: 1683–8.
80 Chen F, Maridakis V, O’Neill EA, Beals C, Radziszewski W,
de Lepeleire I, Van Dyck K, Depre M, Bolognese JA, de Hoon
© 2018 International Society on Thrombosis and Haemostasis
Antiplatelet effects of tyrosine kinase inhibitors 1697
J, Jacquemin M. A randomized clinical trial comparing point-
of-care platelet function assays and bleeding time in healthy
subjects treated with aspirin or clopidogrel. Platelets 2012; 23:
249–58.
81 Nagy M, Mastenbroek TG, Mattheij NJA, de Witt S, Clemetson
KJ, Kirschner J, Schulz AS, Vraetz T, Speckmann C, Braun A,
Cosemans J, Zieger B, Heemskerk JWM. Variable impairment of
platelet functions in patients with severe, genetically linked
immune deficiencies.Haematologica 2018; 103: 540–9.
82 Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rod-
ger MA. Systematic review: the Trousseau syndrome revisited:
should we screen extensively for cancer in patients with venous
thromboembolism? Ann Intern Med 2008; 149: 323–33.
83 Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li
C, Qian J, Zheng C, Zuo Y. Safety and pharmacokinetics of
novel selective vascular endothelial growth factor receptor-2
inhibitor YN968D1 in patients with advanced malignancies.
BMC Cancer 2010; 10: 529–36.
84 Keller G, Schafhausen P, Brummendorf TH. Bosutinib: a dual
SRC/ABL kinase inhibitor for the treatment of chronic myeloid
leukemia. Expert Rev Hematol 2009; 2: 489–97.
85 Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA,
Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han
KH, Paik SW, Robles-Avina J, Kudo M, Yan L, Sobhonslid-
suk A, Komov D, et al. Brivanib versus sorafenib as first-line
therapy in patients with unresectable, advanced hepatocellular
carcinoma: results from the randomized phase III BRISK-FL
study. J Clin Oncol 2013; 31: 3517–24.
86 Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI,
Donskov F, Hammers H, Hutson TE, Lee J-L, Peltola K, Roth
BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DYC,
Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C,
et al. Cabozantinib versus everolimus in advanced renal-cell car-
cinoma. N Engl J Med 2015; 373: 1814–23.
87 Langenberg MH, van Herpen CM, De Bono J, Schellens JH,
Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le
Maulf F, Fielding A, Robertson J, Voest EE. Effective strate-
gies for management of hypertension after vascular endothe-
lial growth factor signaling inhibition therapy: results from a
phase II randomized, factorial, double-blind study of Cedi-
ranib in patients with advanced solid tumors. J Clin Oncol
2009; 27: 6152–9.
88 Soria J-C, Tan DSW, Chiari R, Wu Y-L, Paz-Ares L, Wolf J,
Geater SL, Orlov S, Cortinovis D, Yu C-J, Hochmair M, Cor-
tot AB, Tsai C-M, Moro-Sibilot D, Campelo RG, McCulloch
T, Sen P, Dugan M, Pantano S, Branle F, et al. First-line ceri-
tinib versus platinum-based chemotherapy in advanced ALK-
rearranged non-small-cell lung cancer (ASCEND-4): a ran-
domised, open-label, phase 3 study. Lancet 2017; 389: 917–29.
89 Boespflug A, Thomas L. Cobimetinib and vemurafenib for the
treatment of melanoma. Expert Opin Pharmacother 2016; 17:
1005–11.
90 Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev
Drug Discov 2011; 10: 897–8.
91 Gibney GT, Zager JS. Clinical development of dabrafenib in
BRAF mutant melanoma and other malignancies. Expert Opin
Drug Metab Toxicol 2013; 9: 893–9.
92 Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri
FR, Engelman JA, Koczywas M, Rajan A, Campbell AK,
Gernhardt D, Ruiz-Garcia A, Letrent S, Liang J, Taylor I,
O’Connell JP, Janne PA. A phase 2 trial of dacomitinib (PF-
00299804), an oral, irreversible pan-HER (human epidermal
growth factor receptor) inhibitor, in patients with advanced
non-small cell lung cancer after failure of prior chemotherapy
and erlotinib. Cancer 2014; 120: 1145–54.
93 Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid
leukemia: a review. Ther Clin Risk Manag 2009; 5: 281–9.
94 Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli
E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa
AL, Bouche O, Italiano A, Bauer S, Barone C, Weiss C, Crippa
S, Camozzi M, Castellana R, LeCesne A. Dovitinib in patients
with gastrointestinal stromal tumour refractory and/or intoler-
ant to imatinib. Br J Cancer 2017; 117: 1278–85.
95 Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu
M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial
of entospletinib (GS-9973), a selective spleen tyrosine kinase
inhibitor, in chronic lymphocytic leukemia. Blood 2015; 125:
2336–43.
96 Rocha-Lima CM, Raez LE. Erlotinib (Tarceva) for the treat-
ment of non-small-cell lung cancer and pancreatic cancer.
Pharm. Therap 2009; 34: 554–64.
97 McAdoo SP, Tam FWK. Fostamatinib disodium. Drugs Future
2011; 36: 273–82.
98 Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D,
Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang
H, Song Y, Wu YL, Xu N, Zhou J, Luo R, et al. Icotinib ver-
sus gefitinib in previously treated advanced non-small-cell lung
cancer (ICOGEN): a randomised, double-blind phase 3 non-
inferiority trial. Lancet Oncol 2013; 14: 953–61.
99 Blay J-Y, von Mehren M. Nilotinib: a novel, selective tyrosine
kinase inhibitor. Semin Oncol 2011; 38: S3–9.
100 Kim S-B, Dent R, Im S-A, Espie M, Blau S, Tan AR, Isakoff
SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan
WY, Singel SM, Maslyar DJ, Baselga J. Ipatasertib plus pacli-
taxel versus placebo plus paclitaxel as first-line therapy for
metastatic triple-negative breast cancer (LOTUS): a multicentre,
randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol 2017; 18: 1360–72.
101 Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G,
Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J,
O’Shaughnessy J. Randomized study of lapatinib alone or in
combination with trastuzumab in women with ErbB2-positive,
trastuzumab-refractory metastatic breast cancer. J Clin Oncol
2010; 28: 1124–30.
102 Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS,
Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gia-
noukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska
MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenva-
tinib versus placebo in radioiodine-refractory thyroid cancer. N
Engl J Med 2015; 372: 621–30.
103 Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK,
Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y,
Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Tani-
guchi H, Brun M, Le Maulf F, Girard M, Stowasser S, et al.
Efficacy and safety of nintedanib in idiopathic pulmonary fibro-
sis. N Engl J Med 2014; 370: 2071–82.
104 Goss G, Tsai C-M, Shepherd FA, Bazhenova L, Lee JS, Chang
G-C, Crino L, Satouchi M, Chu Q, Hida T, Han J-Y, Juan O,
Dunphy F, Nishio M, Kang J-H, Majem M, Mann H, Can-
tarini M, Ghiorghiu S, Mitsudomi T. Osimertinib for pretreated
EGFR Thr790Met-positive advanced non-small-cell lung cancer
(AURA2): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol 2016; 17: 1643–52.
105 Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G,
Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau
S, Ravandi F, O’Brien S, Cortes J. Ponatinib as first-line treat-
ment for patients with chronic myeloid leukaemia in chronic
phase: a phase 2 study. Lancet Haematol 2015; 2: e376–83.
106 Ferraro D, Zalcberg J. Regorafenib in gastrointestinal stromal
tumors: clinical evidence and place in therapy. Ther Adv Med
Oncol 2014; 6: 222–8.
107 Casaluce F, Sgambato A, Maione P, Sacco PC, Santabarbara
G, Gridelli C. Selumetinib for the treatment of non-small cell
lung cancer. Exp Opin Invest Drugs 2017; 26: 973–84.
© 2018 International Society on Thrombosis and Haemostasis
1698 B. M. E. Tullemans et al
108 Lugowska I, Koseła-Paterczyk H, Kozak K, Rutkowski P.
Trametinib: a MEK inhibitor for management of metastatic
melanoma. Onco Targets Ther 2015; 8: 2251–9.
109 Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro
M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P,
Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally
advanced or metastatic medullary thyroid cancer: a randomized,
double-blind phase III trial. J Clin Oncol 2012; 30: 134–41.
110 Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E,
Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg
W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D,
Kerr D. Randomized, placebo-controlled, phase III study of
first-line oxaliplatin-based chemotherapy plus PTK787/ZK
222584, an oral vascular endothelial growth factor receptor
inhibitor, in patients with metastatic colorectal adenocarcinoma.
J Clin Oncol 2011; 29: 1997–2003.
111 Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K,
Hirth P. Vemurafenib: the first drug approved for BRAF-
mutant cancer. Nat Rev Drug Discov 2012; 11: 873–86.
© 2018 International Society on Thrombosis and Haemostasis
Antiplatelet effects of tyrosine kinase inhibitors 1699
